Oxford, UK – 14 September 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that its subsidiary Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”), a high-performing full-scope scope AAV manufacturing and innovation business, has signed an agreement with a… Read More
Oxford, UK – 7 September 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based late-stage cell and gene therapy company. The LSA grants the… Read More
Oxford, UK – 16 August 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the release of Homology Medicines’ (“Homology”) quarterly report for the three months ended 30 June 2022. Financial information on Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”)… Read More
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies. Read More
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology. As part of the project, Oxford Biomedica’s LentiStable™ technology… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
Oxford, UK – 14 June 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the recent announcement from Homology Medicines Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company regarding the pheNIX gene therapy trial. The U.S. Food and Drug Administration… Read More
Bedford, Massachusetts – May 6, 2022: Oxford Biomedica Solutions, LLC. (“Oxford Biomedica Solutions”), a new high-performing, full scope AAV manufacturing and innovation business, now offering its ‘Plug & Play’ Platform that has successfully delivered four GMP programs and five Investigational New Drug submissions. Oxford Biomedica Solutions is announcing today that… Read More
London, UK – 27 April 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica”, “the Company” or “the Group”), a leading gene and cell therapy group, gives notice that copies of the 2021 Annual report and accounts and the Notice of Annual General Meeting (“AGM”) are being sent to shareholders. These… Read More
Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica,… Read More
Oxford, UK – 13 April 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, announces the appointment of Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect. Ms. Patel has extensive international experience in manufacturing and… Read More
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or the “Company”), a leading gene and cell therapy group, is pleased to announce that it has… Read More